Striking a balance between access and cost
Since the American Medical Association classified obesity as a disease in 2013, the way we treat the condition has changed. No longer regarded as a lifestyle choice, obesity now represents an opportunity for treatment with drug therapy. Although new drugs like Wegovy and Ozempic have had positive results for those seeking to lose weight, some nagging questions remain.
The best outcomes for patients combine the use of these drugs as part of a comprehensive nutrition management program. Hear from Dr. Sree Chaguturu, Executive Vice President and Chief Medical Officer, CVS Health, as he explains the promise of these drugs, and how payors can strike the balance between access and cost.
Dr. Sree Chaguturu presents on the main stage at Client Forum.
